Sunday, July 26, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2040

Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.

Patents
134

Quick answer

134 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10532101

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10537581

    Vaginal inserted estradiol pharmaceutical compositions and methods

    Compass Therapeutics LLC · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10537642

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10543192

    Glycopyrrolate salts

    Dermira, Inc. · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10544108

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10548863

    Process to prepare treprostinil, the active ingredient in Remodulin®

    United Therapeutics Corporation · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10548875

    Glycopyrrolate salts

    Dermira, Inc. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10550081

    Crystalline freebase forms of a biphenyl compound

    Theravance Biopharma R&D IP, LLC · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10548889

    Compositions of CXCR4 inhibitors and methods of preparation and use

    X4 Pharmaceuticals, Inc. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10558394

    Injectable flowable composition comprising buprenorphine

    Indivior UK Limited · Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10562934

    Modulation of complement activity

    RA PHARMACEUTICALS, INC. · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10563259

    Method of treatment based on polymorphisms of the KCNQ1 gene

    VANDA PHARMACEUTICALS INC. · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10561664

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10570391

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10568891

    Vaginal inserted estradiol pharmaceutical compositions and methods

    Compass Therapeutics LLC · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10568873

    Safranal-sorafenib combination therapy for liver cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10568855

    Compositions and methods for enhancing the efficacy of contraceptive microbicides

    Evofem, Inc. · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10570453

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10583088

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10583180

    Method for treating adenosine deaminase severe combined imunodeficiency

    The Regents of the University of California · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10583144

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10592168

    Injectable flowable composition comprising buprenorphine

    Indivior UK Limited · Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10597377

    Somatostatin modulators and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10597384

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10597657

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10603308

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10611744

    Highly purified pharmaceutical grade tasimelteon

    VANDA PHARMACEUTICALS INC. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10610510

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10611758

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10610511

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10612024

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10610125

    Methods and compositions for cell-proliferation-related disorders

    Agios Pharmaceuticals, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10610527

    Methods for treating immunodeficiency disease

    X4 Pharmaceuticals, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10612027

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. EP 3630112

    KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS

    BAYER AG [DE] · Granted Wed Apr 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10624850

    Emulsion formulations of an NK-1 receptor antagonist and uses thereof

    Heron Therapeutics, Inc. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10632199

    Long-acting polymeric delivery systems

    Heron Therapeutics, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10632114

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10639375

    Progesterone formulations

    Compass Therapeutics LLC · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10646485

    Process of making stable abuse-deterrent oral formulations

    Collegium Pharmaceutical, Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10646443

    Sustained release olanzapine formulations

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10646550

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10646484

    Methods to treat opioid use disorder

    Indivior UK Limited · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10646480

    Formulations of pimavanserin

    ACADIA Pharmaceuticals Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10646481

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10653777

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10653710

    Combination therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10660904

    Optimizing mifepristone levels for cushing's patients

    Corcept Therapeutics Incorporated · Granted Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2040?

134 published patents in our USPTO index have expiration dates falling in calendar year 2040.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.